Catalent utilised two technologies targeting duodenal and sublingual biological barriers through a parallel screening approach to assess the oral delivery potential of Salmon Calcitonin.

This well-known peptide is currently delivered via injection to treat osteoporosis in postmenopausal women. An oral dose is not available due to its poor oral bioavailability.

While Salmon Calcitonin is water soluble, it has poor permeability through tight junctions and limited transcellular pathways doe to its molecular size, geometry, and flexibility.

Catalent’s OptiForm Solution Suite Bio with OptiGel Bio and Zydis Bio technologies were used to overcome duodenal and sublingual barriers with simple candidate formulations.

To find out more about this case study, download this free whitepaper.